卡维地洛预防化疗相关心脏毒性:CECCY 试验
CECCY 为前瞻性随机双盲安慰剂对照研究,纳入 200 例 HER2 阴性乳腺癌、LVEF 正常并接受蒽环类(240 mg/m2)化疗的患者,评估卡维地洛预防心脏毒性。6 个月 LVEF 下降≥10% 的发生率两组无差异(14.5% 对 13.5%,p=1.0),但卡维地洛组肌钙蛋白 I 水平随时间显著更低(p=0.003),舒张功能障碍发生率更低(p=0.039)。
要点
- 卡维地洛未降低 6 个月 LVEF 下降≥10% 的发生率。
- 卡维地洛可显著降低肌钙蛋白 I 水平及舒张功能障碍发生率。
- 蒽环类化疗中早期心脏毒性发生率约为 13.5%–14.5%。
核心结论
- 在当代蒽环类剂量下,卡维地洛对早期 LVEF 下降无影响,但可显著降低肌钙蛋白水平与舒张功能障碍。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照研究,纳入 200 例 HER2 阴性乳腺癌且 LVEF 正常、接受蒽环类(240 mg/m2)化疗的患者,随机接受卡维地洛或安慰剂至化疗结束。
主要发现
- 主要终点(6 个月 LVEF 下降≥10%)在卡维地洛组 14 例(14.5%)、安慰剂组 13 例(13.5%),p=1.0。
- 两组 LVEF 与 B 型利钠肽变化无差异。
- 肌钙蛋白 I 水平随时间变化两组间存在显著差异,卡维地洛组更低(p=0.003)。
- 卡维地洛组舒张功能障碍发生率更低(p=0.039)。
- LV 舒张末期内径随访期间增幅在卡维地洛组有减小趋势(44.1±3.64 mm 至 45.2±3.2 mm 对 44.9±3.6 mm 至 46.4±4.0 mm;p=0.057)。
临床怎么用
- 对接受蒽环类化疗且 LVEF 正常的 HER2 阴性乳腺癌患者,卡维地洛不宜以预防早期 LVEF 下降为目的常规使用。
- 卡维地洛可能有助于降低肌钙蛋白 I 水平及舒张功能障碍,可作为个体化评估的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with β-blockers remains controversial. OBJECTIVES: This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS: The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a ≥10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS: Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 ± 3.64 mm to 45.2 ± 3.2 mm vs. 44.9 ± 3.6 mm to 46.4 ± 4.0 mm; p = 0.057). CONCLUSIONS: In this largest clinical trial of β-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction. (Carvedilol Effect in Preventing Chemotherapy-Induced Cardiotoxicity [CECCY]; NCT01724450).
引用
- Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018. PMID: 29540327. doi:10.1016/j.jacc.2018.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。